211 related articles for article (PubMed ID: 33774007)
1. Cannabinoid receptor agonists from Conus venoms alleviate pain-related behavior in rats.
Jergova S; Perez C; Imperial JS; Gajavelli S; Jain A; Abin A; Olivera BM; Sagen J
Pharmacol Biochem Behav; 2021 Jun; 205():173182. PubMed ID: 33774007
[TBL] [Abstract][Full Text] [Related]
2. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
4. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Romero TR; Resende LC; Guzzo LS; Duarte ID
Anesth Analg; 2013 Feb; 116(2):463-72. PubMed ID: 23302980
[TBL] [Abstract][Full Text] [Related]
5. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain.
Cui JH; Ju J; Yoon MH
Pharmacology; 2013; 92(3-4):150-7. PubMed ID: 24008428
[TBL] [Abstract][Full Text] [Related]
7. Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.
Cumella J; Hernández-Folgado L; Girón R; Sánchez E; Morales P; Hurst DP; Gómez-Cañas M; Gómez-Ruiz M; Pinto DC; Goya P; Reggio PH; Martin MI; Fernández-Ruiz J; Silva AM; Jagerovic N
ChemMedChem; 2012 Mar; 7(3):452-63. PubMed ID: 22302767
[TBL] [Abstract][Full Text] [Related]
8. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
9. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.
Mulpuri Y; Marty VN; Munier JJ; Mackie K; Schmidt BL; Seltzman HH; Spigelman I
Neuropharmacology; 2018 Sep; 139():85-97. PubMed ID: 29981335
[TBL] [Abstract][Full Text] [Related]
10. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.
Hama A; Sagen J
Brain Res; 2011 Sep; 1412():44-54. PubMed ID: 21813113
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
12. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.
Khasabova IA; Gielissen J; Chandiramani A; Harding-Rose C; Odeh DA; Simone DA; Seybold VS
Behav Pharmacol; 2011 Sep; 22(5-6):607-16. PubMed ID: 21610490
[TBL] [Abstract][Full Text] [Related]
13. Spinal cannabinoid CB1 or CB2 receptors activation attenuates mechanical allodynia in streptozotocin-induced diabetic rats.
Gonçalves MR; da Conceição MS; Jesus CHA; Gasparin AT; Rosa ES; da Cunha JM
Behav Pharmacol; 2022 Apr; 33(2&3):158-164. PubMed ID: 32804775
[TBL] [Abstract][Full Text] [Related]
14. Antinociceptive effects of the selective CB2 agonist MT178 in inflammatory and chronic rodent pain models.
Vincenzi F; Targa M; Corciulo C; Tabrizi MA; Merighi S; Gessi S; Saponaro G; Baraldi PG; Borea PA; Varani K
Pain; 2013 Jun; 154(6):864-73. PubMed ID: 23518609
[TBL] [Abstract][Full Text] [Related]
15. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury.
Johanek LM; Simone DA
Pain; 2004 Jun; 109(3):432-442. PubMed ID: 15157704
[TBL] [Abstract][Full Text] [Related]
16. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model.
Cui JH; Kim WM; Lee HG; Kim YO; Kim CM; Yoon MH
Neurosci Lett; 2011 Apr; 493(3):67-71. PubMed ID: 21195743
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
18. Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice.
Veloso CC; Ferreira RCM; Rodrigues VG; Duarte LP; Klein A; Duarte ID; Romero TRL; Perez AC
Inflammopharmacology; 2018 Feb; 26(1):227-233. PubMed ID: 28889355
[TBL] [Abstract][Full Text] [Related]
19. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
20. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
